Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other Non-Current Assets: 2015-2024

Historic Other Non-Current Assets for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to $217,000.

  • Syndax Pharmaceuticals' Other Non-Current Assets changed negligibly% to $217,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $217,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $217,000 for FY2024, which is 53.13% down from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $217,000 for FY2024, which was down 53.13% from $463,000 recorded in FY2023.
  • Syndax Pharmaceuticals' 5-year Other Non-Current Assets high stood at $1.3 million for FY2020, and its period low was $115,000 during FY2021.
  • In the last 3 years, Syndax Pharmaceuticals' Other Non-Current Assets had a median value of $463,000 in 2023 and averaged $495,667.
  • In the last 5 years, Syndax Pharmaceuticals' Other Non-Current Assets spiked by 1,001.74% in 2020 and then tumbled by 90.92% in 2021.
  • Over the past 5 years, Syndax Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $1.3 million in 2020, then tumbled by 90.92% to $115,000 in 2021, then soared by 601.74% to $807,000 in 2022, then plummeted by 42.63% to $463,000 in 2023, then tumbled by 53.13% to $217,000 in 2024.